Endocrinology is closely attributed to Body mass index in his work. Body mass index and Endocrinology are frequently intertwined in his study. He connects Insulin resistance with Type 2 diabetes in his study. In his research, he performs multidisciplinary study on Type 2 diabetes and Diabetes mellitus. He undertakes multidisciplinary investigations into Diabetes mellitus and Glucose tolerance test in his work. Yasuo Akanuma connects Glucose tolerance test with Insulin resistance in his research. His Internal medicine study frequently draws connections between related disciplines such as Insulin oscillation. His Insulin oscillation study typically links adjacent topics like Internal medicine. As part of his studies on Insulin, he often connects relevant subjects like Insulin receptor substrate.
A majority of his Cholesterol research is a blend of other scientific areas, such as Lipoprotein and Triglyceride. By researching both Lipoprotein and Cholesterol, Yasuo Akanuma produces research that crosses academic boundaries. His research is interdisciplinary, bridging the disciplines of Endocrinology and Triglyceride. Yasuo Akanuma regularly ties together related areas like Plasma glucose in his Endocrinology studies. Much of his study explores Internal medicine relationship to Plasma glucose. His research on Insulin often connects related topics like Glucose transporter. His Glucose transporter study frequently draws connections between related disciplines such as Insulin. He incorporates Biochemistry and Cell biology in his research. Yasuo Akanuma incorporates Cell biology and Biochemistry in his research.
Hazard ratio overlaps with fields such as Confidence interval and Proportional hazards model in his research. He performs integrative Confidence interval and Hazard ratio research in his work. As part of his studies on Proportional hazards model, Yasuo Akanuma often connects relevant subjects like Internal medicine. Yasuo Akanuma combines Internal medicine and Pediatrics in his studies. He integrates Pediatrics with Endocrinology in his study. Endocrinology is often connected to Hypoglycemia in his work. He combines Hypoglycemia and Type 2 diabetes in his research. Yasuo Akanuma integrates many fields in his works, including Type 2 diabetes and Body mass index. He integrates Body mass index and Diabetes mellitus in his research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.
Akira Okuno;Hiroyuki Tamemoto;Kazuyuki Tobe;Kohjiro Ueki.
Journal of Clinical Investigation (1998)
Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the japanese population
Kazuo Hara;Philippe Boutin;Yasumichi Mori;Kazuyuki Tobe.
The Mechanisms by Which Both Heterozygous Peroxisome Proliferator-activated Receptor γ (PPARγ) Deficiency and PPARγ Agonist Improve Insulin Resistance
Toshimasa Yamauchi;Junji Kamon;Hironori Waki;Koji Murakami.
Journal of Biological Chemistry (2001)
Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia.
Naoto Kubota;Kazuyuki Tobe;Yasuo Terauchi;Kazuhiro Eto.
Role of NADH Shuttle System in Glucose-Induced Activation of Mitochondrial Metabolism and Insulin Secretion
Kazuhiro Eto;Yoshiharu Tsubamoto;Yasuo Terauchi;Takuya Sugiyama.
Increased insulin sensitivity and hypoglycaemia in mice lacking the p85α subunit of phosphoinositide 3–kinase
Y. Terauchi;Y. Tsuji;S. Satoh;H. Minoura.
Nature Genetics (1999)
A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats.
K Murakami;K Tobe;T Ide;T Mochizuki.
Potential Role of Protein Kinase B in Insulin-induced Glucose Transport, Glycogen Synthesis, and Protein Synthesis
Kohjiro Ueki;Ritsuko Yamamoto-Honda;Yasushi Kaburagi;Toshimasa Yamauchi.
Journal of Biological Chemistry (1998)
Risk factors for worsening to diabetes in subjects with impaired glucose tolerance
T. Kadowaki;Y. Miyake;R. Hagura;Y. Akanuma.
Long-Term Clinical Effects of Epalrestat, an Aldose Reductase Inhibitor, on Diabetic Peripheral Neuropathy: The 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial
Nigishi Hotta;Yasuo Akanuma;Ryuzo Kawamori;Kempei Matsuoka.
Diabetes Care (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: